Gastroprotection of DNA with a synthetic cholic acid analog

E. J. Niedzinski, M. J. Bennett, D. C. Olson, M. H. Nantz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The oral delivery of functional DNA to the gastrointestinal system would constitute a desirable, noninvasive method for potentially treating a variety of diseases. The digestive process, however, remains a formidable barrier. This dilemma may be addressed by using targeted liposomes both to protect the polynucleotide and to deliver the therapeutic DNA with high tissue specificity. The present study represents the initial steps toward developing a novel gene delivery system designed to interact with the enterohepatic receptors of the small intestine. Two cholic acid esters were synthetically modified at position C(3) to incorporate a DNA-binding domain. These novel compounds were evaluated for their ability to protect DNA from the nucleases found in gastrointestinal segments. Additionally, the compounds were screened as a component of a gene delivery vector. Formulations containing the new bile salt derivatives protected DNA from degradation for more than 2 h and were capable of transfecting cultured NIH 3T3 cells.

Original languageEnglish (US)
Pages (from-to)721-727
Number of pages7
JournalLipids
Volume35
Issue number7
StatePublished - 2000

Fingerprint

cholic acid
Cholic Acid
DNA
gene transfer
Genes
Gene Components
polynucleotides
Gene Transfer Techniques
Polynucleotides
NIH 3T3 Cells
Organ Specificity
DNA-binding domains
bile salts
Deoxyribonucleases
nucleases
Bile Acids and Salts
Liposomes
Small Intestine
gastrointestinal system
small intestine

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Food Science
  • Biochemistry

Cite this

Niedzinski, E. J., Bennett, M. J., Olson, D. C., & Nantz, M. H. (2000). Gastroprotection of DNA with a synthetic cholic acid analog. Lipids, 35(7), 721-727.

Gastroprotection of DNA with a synthetic cholic acid analog. / Niedzinski, E. J.; Bennett, M. J.; Olson, D. C.; Nantz, M. H.

In: Lipids, Vol. 35, No. 7, 2000, p. 721-727.

Research output: Contribution to journalArticle

Niedzinski, EJ, Bennett, MJ, Olson, DC & Nantz, MH 2000, 'Gastroprotection of DNA with a synthetic cholic acid analog', Lipids, vol. 35, no. 7, pp. 721-727.
Niedzinski EJ, Bennett MJ, Olson DC, Nantz MH. Gastroprotection of DNA with a synthetic cholic acid analog. Lipids. 2000;35(7):721-727.
Niedzinski, E. J. ; Bennett, M. J. ; Olson, D. C. ; Nantz, M. H. / Gastroprotection of DNA with a synthetic cholic acid analog. In: Lipids. 2000 ; Vol. 35, No. 7. pp. 721-727.
@article{9c30e07512f643bdb6532c2f9b4b7981,
title = "Gastroprotection of DNA with a synthetic cholic acid analog",
abstract = "The oral delivery of functional DNA to the gastrointestinal system would constitute a desirable, noninvasive method for potentially treating a variety of diseases. The digestive process, however, remains a formidable barrier. This dilemma may be addressed by using targeted liposomes both to protect the polynucleotide and to deliver the therapeutic DNA with high tissue specificity. The present study represents the initial steps toward developing a novel gene delivery system designed to interact with the enterohepatic receptors of the small intestine. Two cholic acid esters were synthetically modified at position C(3) to incorporate a DNA-binding domain. These novel compounds were evaluated for their ability to protect DNA from the nucleases found in gastrointestinal segments. Additionally, the compounds were screened as a component of a gene delivery vector. Formulations containing the new bile salt derivatives protected DNA from degradation for more than 2 h and were capable of transfecting cultured NIH 3T3 cells.",
author = "Niedzinski, {E. J.} and Bennett, {M. J.} and Olson, {D. C.} and Nantz, {M. H.}",
year = "2000",
language = "English (US)",
volume = "35",
pages = "721--727",
journal = "Lipids",
issn = "0024-4201",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Gastroprotection of DNA with a synthetic cholic acid analog

AU - Niedzinski, E. J.

AU - Bennett, M. J.

AU - Olson, D. C.

AU - Nantz, M. H.

PY - 2000

Y1 - 2000

N2 - The oral delivery of functional DNA to the gastrointestinal system would constitute a desirable, noninvasive method for potentially treating a variety of diseases. The digestive process, however, remains a formidable barrier. This dilemma may be addressed by using targeted liposomes both to protect the polynucleotide and to deliver the therapeutic DNA with high tissue specificity. The present study represents the initial steps toward developing a novel gene delivery system designed to interact with the enterohepatic receptors of the small intestine. Two cholic acid esters were synthetically modified at position C(3) to incorporate a DNA-binding domain. These novel compounds were evaluated for their ability to protect DNA from the nucleases found in gastrointestinal segments. Additionally, the compounds were screened as a component of a gene delivery vector. Formulations containing the new bile salt derivatives protected DNA from degradation for more than 2 h and were capable of transfecting cultured NIH 3T3 cells.

AB - The oral delivery of functional DNA to the gastrointestinal system would constitute a desirable, noninvasive method for potentially treating a variety of diseases. The digestive process, however, remains a formidable barrier. This dilemma may be addressed by using targeted liposomes both to protect the polynucleotide and to deliver the therapeutic DNA with high tissue specificity. The present study represents the initial steps toward developing a novel gene delivery system designed to interact with the enterohepatic receptors of the small intestine. Two cholic acid esters were synthetically modified at position C(3) to incorporate a DNA-binding domain. These novel compounds were evaluated for their ability to protect DNA from the nucleases found in gastrointestinal segments. Additionally, the compounds were screened as a component of a gene delivery vector. Formulations containing the new bile salt derivatives protected DNA from degradation for more than 2 h and were capable of transfecting cultured NIH 3T3 cells.

UR - http://www.scopus.com/inward/record.url?scp=0033868385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033868385&partnerID=8YFLogxK

M3 - Article

C2 - 10941872

AN - SCOPUS:0033868385

VL - 35

SP - 721

EP - 727

JO - Lipids

JF - Lipids

SN - 0024-4201

IS - 7

ER -